Key facts
- This page summarizes Vincent Milano's Form 4 filing for Aceragen, Inc..
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 11 Aug 2023, 16:30.
Vincent Milano - 10 Aug 2023 Form 4 Insider Report for Aceragen, Inc.
- Reporting relationship
- Director
- Issuer ticker
- N/A
- Reported as of
- 10 Aug 2023
- Net transaction value
- -$1,750
- SEC form
- 4
- Accepted by SEC
- 11 Aug 2023, 16:30:24 UTC
- Prior SEC filing
- 15 Jun 2023
- Next SEC filing
- 05 Sep 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Vincent J. Milano
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Vincent Milano filed Form 4 for Aceragen, Inc. on 11 Aug 2023.
Change
- Previous filing in this sequence was filed on 15 Jun 2023.
- Current net transaction value: -$1,750.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
ACGN
transaction
Common Stock
Sale
- Transaction value
- $1,750
- Shares
- -3,283
- Change %
- -27%
- Price
- $0.5331
- Shares after
- 8,987
- Date
- 10 Aug 2023
- Ownership
- Direct
- Footnotes
- F1, F2, F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
The reported price in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $0.52 to $0.5513 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Footnote F2
The shares reported on this Form 4 have been adjusted to reflect the Issuer's 1-for-17 reverse stock split of its common stock, effective January 17, 2023.
Footnote F3
Of the reported securities beneficially owned, 544 shares are represented by unvested Restricted Stock Units.